

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 October 2020 (22.10.2020)



(10) International Publication Number
WO 2020/212352 A1

(51) International Patent Classification:

C07C 237/06 (2006.01) C07C 41/30 (2006.01)
C07C 231/12 (2006.01)

(21) International Application Number:

PCT/EP2020/060470

(22) International Filing Date:

14 April 2020 (14.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19169715.0 17 April 2019 (17.04.2019) EP

(71) Applicant: NEWRON PHARMACEUTICALS S.P.A.
[IT/IT]; Via Antonio Meucci, 3, 20091 BRESSO (MI) (IT).

(72) Inventors: LEONG, William; 342 Edgewood Avenue,
Westfield, New Jersey 07090 (US). LAN, Dongxiao; South
Bridge Bay Port Industrial Build. No. 10, Fengxian District,
Shanghai (CN). ZHANG, Weifang; No. 70, Room 403
Zhayuan New Village, Xidu Community, Fengxian District,
Shanghai (CN). FANG, Xiang; No. 121, 859 Lianye Road,
Fengxian District, Shanghai (CN). WU, Sizhong; Ziwei
Road 667, Building 168, Zhangjiang Town, Pudong New
Area, Shanghai (CN).

(74) Agent: BARCHIELLI, Giovanna; c/o BIANCHETTI
BRACCO MINOJA S.R.L., Via Plinio, 63, 20129
MILANO (IT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,


DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES



(57) Abstract: The present invention refers to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R is (C₃-C₁₀)alkyl, or ω-trifluoro(C₃-C₁₀)alkyl; R₁ and R₂ are, independently, hydrogen, hydroxy, (C₁-C₈) alkoxy, (C₁-C₈) alkylthio, halo, trifluoromethyl or 2,2,2-trifluoroethyl; or one of R₁ and R₂ is in ortho position to the R-O- group and, taken together with the same R-O-, represents a Formula (A) group where R₆ is (C₂-C₉)alkyl; R₃ and R₄ are, independently, hydrogen, (C₁-C₄)alkyl; or R₄ is hydrogen and R₅ is a group selected from -CH₂-OH, -CH₂-O-(C₁-C₆)alkyl, -CH(CH₃)-OH, -(CH₂)₂-S-CH₃, benzyl and 4-hydroxybenzyl; or R₄ and R₅, taken together with the adjacent carbon atom, form a (C₃-C₆)cycloalkyl residue; R₅ and R₆ are independently hydrogen or (C₁-C₆)alkyl; or taken together with the adjacent nitrogen atom form a 5-6 membered monocyclic saturated heterocycle, optionally containing one additional heteroatom chosen among -O-, -S- and -NR₇- where R₇ is hydrogen or (C₁-C₆) alkyl; and wherein optionally one or more hydrogen atom in the groups R, R₁, R₂, R₃, R₄, R₅ and R₆, preferably in the R group, can be substituted by a deuterium atom.